Stay updated with breaking news from Barrett Katz. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- VRDN-001 topline clinical results for THRIVE and THRIVE-2 on track for mid-2024 and year-end 2024 in patients with active and chronic thyroid eye disease , respectively - - Subcutaneous VRDN-003...
- VRDN-001 data demonstrated clinically meaningful and rapid improvement in signs and symptoms of chronic TED at week 6 after receiving two infusions of VRDN-001 10 mg/kg or 3 mg/kg – - Ongoing THRIVE Phase 3 trial in patients with active TED amended to reflect Viridian’s confidence in 5-dose regimen and key stakeholder feedback on evolving TED treatment paradigm - - THRIVE-2 Phase 3 trial in patients with chronic TED expected to start in third quarter 2023 – - 3 mg/kg data support low-volume subcutaneous (SC) dosing profile for Company’s SC candidates in TED - - Viridi...
Needham & Company LLC reissued their buy rating on shares of Viridian Therapeutics (NASDAQ:VRDN – Get Rating) in a research report released on Monday, Benzinga reports. They currently have a $47.00 target price on the stock. A number of other brokerages also recently commented on VRDN. B. Riley boosted their price objective on Viridian Therapeutics […]
MetLife Investment Management LLC raised its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Rating) by 44.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,843 shares of the company’s stock after acquiring an additional 6,129 shares during the quarter. […]
Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Rating) have been given a consensus recommendation of “Buy” by the twelve brokerages that are currently covering the company, MarketBeat.com reports. Nine research analysts have rated the stock with a buy rating. The average 12 month target price among analysts that have issued ratings on the stock […]